Neurobo Pharmaceuticals is expected to report top data from two parts of MASH's ongoing phase 2a clinical trial in the fourth quarter of this year
NeuroBo Pharmaceuticals预计将在今年第四季度报告Mash正在进行的2a期临床试验的两个部分的顶级数据
Neurobo Pharmaceuticals is expected to report top data from two parts of MASH's ongoing phase 2a clinical trial in the fourth quarter of this year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.